Drug intelligence / Profile preview

heptamethine carbocyanine dye-DOTA conjugate

Development stage
Preclinical
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules, Nanoparticles → Drug Delivery Systems
Administration
Intravenous
01

Overview

Heptamethine carbocyanine dye-DOTA conjugates are a class of tumor-targeting agents that combine a near-infrared fluorescent (NIRF) heptamethine carbocyanine dye with the chelator DOTA (dodecane tetraacetic acid), often for radiolabeling with therapeutic or diagnostic radionuclides. These agents exploit the preferential accumulation of heptamethine dyes in malignant cells due to mechanisms such as organic anion transporting polypeptide (OATP)-mediated uptake and hypoxia-inducible factor 1α activity. The DOTA moiety enables stable chelation of radionuclides like lutetium-177 or gallium-68 for targeted radiotherapy or imaging. In preclinical models, these conjugates demonstrate high tumor specificity, prolonged retention at tumor sites, and effective inhibition of tumor growth with minimal toxicity to normal tissues. They are being developed primarily for cancer therapy and molecular imaging applications[1][2][5].

Other names
heptamethine cyanine dye-DOTA conjugateDOTA-heptamethine carbocyanine dye conjugate
02

Targets

SLCO1B3 (Organic anion transporting polypeptide 1B3)OATP (Organic anion transporting polypeptides)

Beyond the preview

Go deeper on heptamethine carbocyanine dye-DOTA conjugate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on heptamethine carbocyanine dye-DOTA conjugate.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call